NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

By sjmartinez • October 27, 2024

Wainberg ZA, M O'Reilly E. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat Rev Clin Oncol. 2024 Oct 25. doi: 10.1038/s41571-024-00952-5. Epub ahead of print. PMID: 39455872.

Tags: Hematology/Oncology, Publications

Related Posts

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Starr S, Zhang J, Lin L, Shen J, Gamalong G, Litwin MS, Drakaki A, Chamie K. Insurance remains a major source of disparity for patients[...]

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia[...]

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]